Novavax’s money is going in the wrong direction

Off Biotech, biotechnology, Business, drug development, drug prices, drug pricing, global health, government agencies, Health, Human Health, Life Sciences, Medicine, Pharma, Pharmaceuticals, Politics, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

Read the rest…

Read Original Article: Novavax’s money is going in the wrong direction »

About The Author